Heart drug trial offers hope for deadly lung condition
NCT ID NCT06554301
Summary
This early-stage study is testing if empagliflozin, a medication typically used for diabetes and heart failure, can help control pulmonary arterial hypertension (PAH)—a serious condition causing high blood pressure in the lungs. The trial will involve 72 adults with PAH who will take either the drug or a placebo pill daily for 12 weeks alongside their standard treatments. Researchers aim to see if the drug safely reduces lung pressure, improves heart function, and helps patients walk farther.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.